92,691 Shares in Emergent BioSolutions Inc. (NYSE:EBS) Acquired by 683 Capital Management LLC

683 Capital Management LLC acquired a new position in shares of Emergent BioSolutions Inc. (NYSE:EBS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 92,691 shares of the biopharmaceutical company's stock, valued at approximately $886,000. 683 Capital Management LLC owned about 0.17% of Emergent BioSolutions as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors also recently added to or reduced their stakes in the company. Covestor Ltd boosted its position in shares of Emergent BioSolutions by 5,458.5% during the 4th quarter. Covestor Ltd now owns 2,946 shares of the biopharmaceutical company's stock valued at $28,000 after acquiring an additional 2,893 shares during the last quarter. Northern Trust Corp increased its stake in Emergent BioSolutions by 2.6% during the fourth quarter. Northern Trust Corp now owns 145,889 shares of the biopharmaceutical company's stock worth $1,395,000 after acquiring an additional 3,692 shares during the last quarter. LPL Financial LLC lifted its stake in shares of Emergent BioSolutions by 34.5% in the 4th quarter. LPL Financial LLC now owns 15,120 shares of the biopharmaceutical company's stock valued at $145,000 after purchasing an additional 3,875 shares during the last quarter. Federated Hermes Inc. increased its position in shares of Emergent BioSolutions by 2.2% during the 4th quarter. Federated Hermes Inc. now owns 277,810 shares of the biopharmaceutical company's stock worth $2,656,000 after purchasing an additional 6,058 shares during the last quarter. Finally, SBI Securities Co. Ltd. acquired a new position in Emergent BioSolutions in the fourth quarter valued at about $63,000. 78.40% of the stock is currently owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

EBS has been the topic of a number of research analyst reports. HC Wainwright reissued a "buy" rating and issued a $15.00 price target on shares of Emergent BioSolutions in a research note on Tuesday, April 1st. StockNews.com lowered Emergent BioSolutions from a "buy" rating to a "hold" rating in a research report on Wednesday, March 5th.

Emergent BioSolutions Price Performance

Emergent BioSolutions stock opened at $4.91 on Friday. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30. Emergent BioSolutions Inc. has a 52-week low of $2.82 and a 52-week high of $15.10. The firm has a market cap of $266.69 million, a PE ratio of -1.20 and a beta of 2.14. The company's 50 day moving average is $5.35 and its two-hundred day moving average is $8.08.

Emergent BioSolutions (NYSE:EBS - Get Free Report) last announced its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.35) by $0.40. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. The business had revenue of $194.70 million for the quarter, compared to analysts' expectations of $254.67 million. During the same period last year, the firm earned ($0.77) earnings per share. On average, research analysts expect that Emergent BioSolutions Inc. will post -0.63 EPS for the current fiscal year.

Emergent BioSolutions declared that its board has approved a stock repurchase plan on Monday, March 31st that allows the company to repurchase $50.00 million in outstanding shares. This repurchase authorization allows the biopharmaceutical company to buy up to 19% of its shares through open market purchases. Shares repurchase plans are typically a sign that the company's board of directors believes its stock is undervalued.

Insider Activity at Emergent BioSolutions

In other Emergent BioSolutions news, Director Neal Franklin Fowler sold 35,000 shares of the stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total value of $204,050.00. Following the sale, the director now directly owns 101,100 shares of the company's stock, valued at approximately $589,413. This represents a 25.72 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. 1.20% of the stock is owned by corporate insiders.

Emergent BioSolutions Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.